EN DE
Watch Positron Corporation for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Positron Corporation (POSC) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Positron Corporation stock $0.84, price $1.72, that is 51.2% below the price, quality 11 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

PC Positron Corporation logo Thin data Nov 10, 2026

Positron Corporation

POSC · US
Very expensive, weak quality

Our calculation puts a fair price 51% below what the stock costs today.

Low debt
Fair value $0.8400 · Strongly overvalued
Quality 11/100
Weak Growth (revenue 5y −10.9 %/yr in USD)
Negative free cash flow
Trails peers (1/6)
Narrow moat 23/100 · thin data
Thin data
Estimate
Watch Positron Corporation for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$2.82 $0.1602 Fair Value $0.8400 Oct 2020 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.1602 – $2.82 · fair‑value band $0.6300 – $1.04 · the $1.72 price screens above the $0.8400 fair value. As of Nov 10, 2026.

Follow Positron in your weekly email

Every Wednesday you see whether Positron is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Positron Corporation, a medical technology company, co-develops, manufactures, and sells positron emission tomography and PET-computed tomography imaging systems in the United States.

Show moreShow less

The company offers Attrius PET and NeuSight PET-CT 64-slice used in non-invasive diagnosis and evaluation of coronary artery disease and supports various molecular imaging applications, including cardiology, oncology, and neurology.

It also provides clinical and technical support services, such as physician interpretation training, nurse and technologist training, billing and prior-authorization assistance, physician over-read services, 24/7 clinical and technical support, priority response with after-hours service availability, equipment uptime guarantees and software upgrades, and remote system diagnostics and maintenance capabilities.

The company sells its products through internal sales and marketing team. It serves healthcare providers, imaging centers, hospitals, and cardiology practices. The company was incorporated in 1983 and is headquartered in North Tonawanda, New York.

Stock analysis

Positron Corporation (POSC) currently trades at $1.72, while our estimate is $0.8400, 51% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.6300 (bear) to $1.04 (bull), the price of $1.72 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 11/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Positron Corporation reported revenue of $461K in FY2025 versus $882K in FY2021, a compound −15.0%/yr. Reported net income was −$10.6M in FY2025.

Key figures

Market cap $56.5M Micro · EPS (TTM) $−0.3200 · Return on equity −2,694% · Return on assets (EBIT) −131% (5-year average) · Operating margin −719% · Revenue (TTM) $445K · Revenue growth (YoY) −6.9% · Free cash flow −$4.8M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (low confidence).

What moves the price

The share trades about 33% below its 52-week high and 31% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 8% fair-value upside, at −51%, POSC screens richer than that median.

Fair Value

Bear $0.6300 Fair Value $0.8400 Bull $1.04
Price $1.72 · Downside -51.2%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 11/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 0
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 47
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 49
How calm the share price moves, does not count
Price momentum 38
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 37
Distance to the 52-week high, does not count
New shares 8
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−21.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−14.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.9%
Start year 2020 (pandemic)
Revenue growth 33 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−7.5% (2020) → −2,275.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

POSC screens overvalued: fair value 51% below the price. Compare with Abbott Laboratories, →

Compare Positron Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 402 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 11 · Bottom 25%
Fair Value upside −51.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −6.9% · Bottom 25%
Balance sheet
Debt / equity 0.01× · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 39.13× · Priciest 25%
PEG 73.60× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 17
FUTURE (revenue growth)0 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 34

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥178.92 ¥202.57 +13% vs POSC
DexCom, Inc DXCM $79.92 $89.18 +12% vs POSC
Stryker Corporation SYK $324.29 $358.30 +10% vs POSC
STERIS plc STE $257.12 $279.53 +9% vs POSC
Boston Scientific Corporation BSX $44.70 $48.42 +8% vs POSC
GE HealthCare Technologies Inc GEHC $83.65 $69.92 −16% vs POSC
Edwards Lifesciences Corporation EW $104.01 $81.94 −21% vs POSC
Abbott Laboratories, ABT $110.46 $75.28 −32% vs POSC
Medtronic plc MDT $101.59 $65.61 −35% vs POSC
Koninklijke Philips N.V PHIA €27.06 €15.23 −44% vs POSC

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Positron Corporation: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Positron Corporation Fair Value". https://www.fairvalue-calculator.com/stock/POSC

Frequently asked questions

Is Positron Corporation (POSC) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.8400 versus a price of $1.72, about 51% lower (overvalued).
What is the fair value of POSC?
Our estimate for Positron Corporation is $0.8400 (as of Nov 10, 2026), built from audited fundamentals. The current price: $1.72.
What is the quality score of POSC?
Positron Corporation has a Quality Score of 11/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Positron Corporation (POSC)?
Our calculated price target is the estimate of $0.8400 (as of Nov 10, 2026). Cautious scenario $0.6300, optimistic scenario $1.04. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Positron Corporation stock forecast for 2026?
Our estimate puts fair value at $0.8400, about 51% lower versus a price of $1.72 (overvalued). Cautious scenario $0.6300, optimistic scenario $1.04. The calculation is refreshed regularly with new filings.
What is the revenue of Positron Corporation (POSC)?
Positron Corporation reported trailing-twelve-month revenue of about $445K (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Positron Corporation (POSC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Positron Corporation it is $0.8400 per share (as of Nov 10, 2026), against a price of $1.72.
Is Positron Corporation stock overvalued or undervalued in 2026?
As of Nov 10, 2026, POSC trades above its calculated fair value: price $1.72, fair value $0.8400, a gap of about −51% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of POSC?
No. The price is what the market pays today ($1.72); the fair value is what the company's own numbers justify ($0.8400). For Positron Corporation the two are $0.8800 per share apart. That gap is exactly why we show both numbers side by side.
How much is Positron Corporation worth?
The market values Positron Corporation at about $56.5M (market capitalisation, as of Nov 10, 2026). Per share that is $1.72; our models calculate a fair value of $0.8400 per share.
What do the bullish and bearish scenarios say about POSC?
Our models span a range for Positron Corporation: cautious scenario $0.6300, base $0.8400, optimistic $1.04 per share (as of Nov 10, 2026, price $1.72). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of POSC?
The PEG ratio of Positron Corporation is 73.60 (P/E divided by earnings growth, as of Nov 10, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Positron Corporation (POSC)?
Balance-sheet figures for Positron Corporation (as of Nov 10, 2026): debt of 0.01 per unit of equity. They feed the Quality Score of 11/100, which measures business quality independently of the share price.
How far is POSC from its 52-week high?
Positron Corporation trades at $1.72, about 33% below its 52-week high of $2.56 and 31% above the low of $1.31 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $0.8400 is for.
Which stocks are comparable to Positron Corporation?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Positron Corporation stock attractive at the current price?
The data as of Nov 10, 2026: price $1.72, calculated fair value $0.8400 (−51%), Quality Score 11/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Positron Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Positron Corporation (POSC)?
The closing price on Nov 10, 2026 was $1.72. Our estimate is $0.8400, about 51% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Positron Corporation right now?
The price sits above even our optimistic bull case ($1.04). The favourable scenario is already priced in. Weak quality (11/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Positron Corporation

How large is the market capitalisation of Positron Corporation (POSC)?
The market capitalisation of Positron Corporation is $56.5M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Positron Corporation (POSC)?
Earnings per share at Positron Corporation are $−0.3200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Positron Corporation (POSC)?
The return on equity (ROE) of Positron Corporation is −2,694% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Positron Corporation (POSC)?
On an EBIT basis the return on assets of Positron Corporation is −131% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Positron Corporation (POSC)?
The operating margin of Positron Corporation is −719% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Positron Corporation (POSC)?
Revenue at Positron Corporation is growing −6.9% versus a year earlier (3y avg −14.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Positron Corporation (POSC) generate?
The free cash flow of Positron Corporation is −$4.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Positron Corporation (POSC) hold?
Positron Corporation holds more cash than debt, $573K net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Positron Corporation in the live analysis

One click puts Positron Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.